General Information of Drug (ID: DMANC59)

Drug Name
AZD-3241 Drug Info
Synonyms Parkinson's disease therapeutic, AstraZeneca
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [1]
Cross-matching ID
PubChem CID
11528958
CAS Number
CAS 890655-80-8
TTD Drug ID
DMANC59

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Myeloperoxidase (MPO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
E-101 DMM1YC4 Infectious disease 1A00-CA43.1 Phase 3 [3]
Mitiperstat DM0BL2G Heart failure with preserved ejection fraction BD11.0 Phase 2/3 [4]
AZD4831 DMRP3N8 Heart failure BD10-BD13 Phase 1 [5]
AZD5904 DM8SCON Chronic obstructive pulmonary disease CA22 Discontinued in Phase 1 [6]
INV-311 DM8BZVI Inflammation 1A00-CA43.1 Investigative [7]
4-aminobenzoic acid hydrazide DMP2GN7 Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloperoxidase (MPO) TTVCZPI PERM_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02388295) AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients. U.S. National Institutes of Health.
2 Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.
3 In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42.
4 Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65(17):11485-11496.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2789).
8 Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010 Nov;335(2):389-400.